Bad expression predicts outcome in patients treated with tamoxifen

[1]  J. Bartlett,et al.  The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells. , 2006, Cancer research.

[2]  青儀 健二郎,et al.  What's going on 乳癌 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group(EBCTCG). Lancet. 2005; 365: 1687-717. PMID: 15894097.--早期乳癌に対する化学療法・内分泌療法が乳癌再発・15年生存率に及 , 2006 .

[3]  S. Willis,et al.  Life in the balance: how BH3-only proteins induce apoptosis. , 2005, Current opinion in cell biology.

[4]  J. Bartlett,et al.  AKT activation predicts outcome in breast cancer patients treated with tamoxifen , 2005, The Journal of pathology.

[5]  R. Kim.  Unknotting the roles of Bcl-2 and Bcl-xL in cell death. , 2005, Biochemical and biophysical research communications.

[6]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[7]  E. McDermott,et al.  Expression of SRC-1, AIB1, and PEA3 in HER2 mediated endocrine resistant breast cancer; a predictive role for SRC-1 , 2004, Journal of Clinical Pathology.

[8]  O. Ortmann,et al.  Tamoxifen long-term treatment in vitro alters the apoptotic response of MCF-7 breast cancer cells , 2004, Anti-cancer drugs.

[9]  R. Nicholson,et al.  Increased Constitutive Activity of PKB/Akt in Tamoxifen Resistant Breast Cancer MCF-7 Cells , 2004, Breast Cancer Research and Treatment.

[10]  J. Wimalasena,et al.  Estradiol abrogates apoptosis in breast cancer cells through inactivation of BAD: Ras-dependent nongenomic pathways requiring signaling through ERK and Akt. , 2004, Molecular biology of the cell.

[11]  W. Gradishar.  Tamoxifen--what next? , 2004, The oncologist.

[12]  R. Schiff,et al.  Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. , 2004, Journal of the National Cancer Institute.

[13]  P. Lønning,et al.  Cognitive ability in childhood and cognitive decline in mid-life: longitudinal birth cohort study , 2003, BMJ : British Medical Journal.

[14]  S. Korsmeyer,et al.  Cell Death Critical Control Points , 2004, Cell.

[15]  Jiang Shou,et al.  Cross-Talk between Estrogen Receptor and Growth Factor Pathways as a Molecular Target for Overcoming Endocrine Resistance , 2004, Clinical Cancer Research.

[16]  Sarkis Meterissian,et al.  Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer. , 2004, Journal of the American College of Surgeons.

[17]  J. R. Reeves,et al.  Outcome and human epidermal growth factor receptor (HER) 1–4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling , 2004, Breast Cancer Research.

[18]  J. Daoud,et al.  Immunohistochemical Status of p53, MDM2, bcl2, bax, and ER in Invasive Ductal Breast Carcinoma in Tunisian Patients , 2003, Annals of the New York Academy of Sciences.

[19]  A. Wellstein,et al.  Effect of estradiol on estrogen receptor-α gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway , 2003, Oncogene.

[20]  G. Mills,et al.  HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells , 2003, Oncogene.

[21]  S. Hilsenbeck,et al.  Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. , 2003, Journal of the National Cancer Institute.

[22]  Takashi Tsuruo,et al.  Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal , 2003, Cancer science.

[23]  M. Dowsett,et al.  Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  P. Dennis,et al.  Activation of the PI3K/Akt pathway and chemotherapeutic resistance. , 2002, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[25]  P. Dennis,et al.  Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. , 2002, Molecular cancer therapeutics.

[26]  J. Nesland,et al.  Reduced expression of both Bax and Bcl‐2 is independently associated with lymph node metastasis in human breast carcinomas , 2002, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[27]  J E Paciga,et al.  Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. , 2001, Cancer research.

[28]  M. Mann,et al.  p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[29]  J. Martinou,et al.  Bax Is Present as a High Molecular Weight Oligomer/Complex in the Mitochondrial Membrane of Apoptotic Cells* , 2001, The Journal of Biological Chemistry.

[30]  Simak Ali,et al.  Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α , 2001, The Journal of Biological Chemistry.

[31]  M. Hung,et al.  Overexpression of ErbB2 in cancer and ErbB2-targeting strategies , 2000, Oncogene.

[32]  D. Cameron,et al.  Effective tamoxifen therapy of breast cancer involves both antiproliferative and pro-apoptotic changes. , 2000, European journal of cancer.

[33]  H. Ruan,et al.  p90RSK Blocks Bad-mediated Cell Death via a Protein Kinase C-dependent Pathway* , 1999, The Journal of Biological Chemistry.

[34]  R. Lanz,et al.  Nuclear receptor coregulators: cellular and molecular biology. , 1999, Endocrine reviews.

[35]  John C. Lee,et al.  Identification of Mitogen-activated Protein (MAP) Kinase-activated Protein Kinase-3, a Novel Substrate of CSBP p38 MAP Kinase (*) , 1996, The Journal of Biological Chemistry.

[36]  Daniel Metzger,et al.  Activation of the Estrogen Receptor Through Phosphorylation by Mitogen-Activated Protein Kinase , 1995, Science.